Results for tag: "Biosimilar Interleukins"

In biotechnology, the biosimilar interleukins market involves the development and commercialization of biosimilar products that are analogous to original biologic interleukins. Interleukins are a group of cytokines expressed by white blood cells (leukocytes) that play a pivotal role in immunomodulation, cell communication, inflammation, and the activation of cellular responses to infection or disease. Biologic interleukins are therapeutic proteins manufactured in living systems and used in the treatment of various medical conditions including cancer, autoimmune diseases, and inflammatory disorders. Biosimilars are near-identical copies of an approved original biologic medicine whose patent has expired, akin to generic versions of traditional pharmaceuticals but with nuanced differences due to their complex structure and production methods. Developing biosimilars requires expertise in biotechnology and rigorous regulatory processes to ensure their safety, purity, and efficacy. As these biosimilar products enter the market, they offer an alternative to the branded originals, potentially reducing healthcare costs and increasing patient access to vital therapies. Several companies are active in the biosimilar interleukins market, including Amgen, Novartis (through its generics division Sandoz), Pfizer, Eli Lilly and Company, Samsung Bioepis, and Biocon. These companies have varying portfolios of biosimilar products either on the market or in the pipeline, addressing the demand for cost-effective biologic therapies. Show Less Read more